Second multistate outbreak of tuberculosis caused by a bone allograft product
Schildknecht, K. R.; Williams, P. M.; Schwartz, N. G.; Haddad, M. B.; Stewart, R. J.; Annambhotla, P.; Basavaraju, S. V.; Nabity, S. A.; Keh, C. E.; Calvet, H. M.; Zahn, M. M.; Beltran, R.; Cortez, A.; Lomeli, A.; Percak, J. M.; Gooze, L. L.; Coloma, M.; Shaw, T.; Davidson, P. J.; Smith, S. R.; Dickson, R. P.; Kaul, D. R.; Gonzalez, A. R.; Rodriguez, G.; Decimo, A.; Sanchez, A.; Armitige, L. Y.; Stapleton, J.; Lacassagne, M.; Brown, C.; Zheng, C.; Ali, J.; Wolfe, A. W.; Young, L. R.; Ariail, K.; Behm, H.; Jordan, H. T.; Spencer, M.; Nilsen, D. M.; Goradia, R.; Montoya Denison, B.; Burgos, M.;
Show abstract
Tuberculosis screening is not mandatory for prospective tissue donors. In 2021 and 2023, two different bone allograft products caused nationwide tuberculosis outbreaks. We assessed the morbidity and mortality of the second outbreak and reviewed donor and tissue screening to identify deficiencies. Thirty-six people residing in nine states received the product during spinal and dental procedures. Twenty-seven recipients had tuberculosis infection, 11 had microbiologic or imaging evidence of tuberculosis disease, and two died from tuberculosis within 12 months of outbreak detection. Another recipient died from tuberculosis nearly 3 years after product implantation. The bone donor died of pneumonia and septic shock. Polymerase chain reaction testing of the product before and after distribution did not detect Mycobacterium tuberculosis. Mycobacterial culture was not performed until after outbreak detection, when M. tuberculosis was isolated from 2 of 6 unused product units. This outbreak demonstrates persistent gaps in tissue transplant safety. Appropriate selection of donors and mycobacterial culture of donated tissues could reduce but not eliminate the risk of M. tuberculosis transmission. Therefore, it is important that clinicians monitor tissue recipients and promptly report adverse events to tissue establishments and health authorities.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial 88%
- The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients 87%
- Adequacy of serial self-performed SARS-CoV-2 rapid antigen-detection testing for longitudinal mass screening in the workplace 86%
Similar papers in this journal
- Comprehensive characterization of COVID-19 patients with repeatedly positive SARS-CoV-2 tests using a large US electronic health record database 87%
- Evaluating the feasibility, sensitivity, and specificity of next-generation molecular methods for pleural infection diagnosis 86%
- Investigating sensitivity of nasal or throat (ISNOT): A combination of both swabs increases sensitivity of SARS-CoV-2 rapid antigen tests 86%
Similar papers in this journal
- Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 86%
- Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial 86%
- SARS-CoV-2 vaccine antibody response and breakthrough infection in dialysis 85%
Similar papers in this journal
- A Pilot Randomized Controlled Trial of de novo Belatacept-Based Immunosuppression in Lung Transplantation 91%
- Balancing Equity and HLA Matching in Deceased-Donor Kidney Allocation with Eplet Mismatch 90%
- SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study) 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.